Remgro Limited reported unaudited consolidated earnings results for the six months ended December 31, 2012. For the period, the company reported sales of ZAR 7,860 million compared to ZAR 6,883 million a year ago. Consolidated profit before tax was ZAR 672 million compared to ZAR 1,987 million a year ago. Consolidated profit after tax was ZAR 534 million compared to ZAR 1,614 million a year ago. Net profit for the period attributable to equity holders was ZAR 1,891 million or 362.4 cents per diluted share compared to ZAR 3,944 million or 758.6 cents per diluted share a year ago. Headline earnings were ZAR 1,719 million or 328.7 cents per diluted share compared to ZAR 2,649 million or 508.2 cents per diluted share a year ago. Net cash inflow from operating activities was ZAR 335 million compared to net cash outflow from operating activities of ZAR 148 million a year ago. Total earnings decreased by 52.1%, mainly as a result of the losses relating to Mediclinic's refinancing transaction amounting to ZAR 1,423 million accounted for during the period under review, as well as capital gains amounting to ZAR 1,099 million accounted for in the comparative period on the disposal of RMBH shares and RMI shares to Royal Bafokeng Holdings (Pty) Limited, the disposal of Tracker and the KTI and Tiso merger.

The Board of Remgro also approved the retirement of Mrs. J A Preller as an executive director from the Board with effect from March 31, 2013.

The company announced an interim gross dividend of 145 cents per share compared to 126 cents per share last year, has been declared out of income reserves in respect of both the ordinary shares of no par value and the unlisted B ordinary shares of no par value, for the half-year to December 31, 2012. The dividend will be payable on April 22, 2013 to the shareholders of record on April 19, 2013. The shares trade ex dividend date is April 15, 2013.